A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS
Frontiers in Cardiovascular Medicine · 13.05.2024 · 11
DOI: 10.3389/fcvm.2024.1363382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 13.05.2024. Verfasst von Haowen Tan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To identify the most commonly reported drugs associated with QT interval prolongation in the FDA Adverse Event Reporting System (FAERS) and evaluate their risk for QT interval prolongation.
Methods
We employed the preferred term (PT) “electrocardiogram QT prolonged” from the Medical Dictionary for Regulatory Activities (MedDRA) 26.0 to identify adverse drug events (ADEs) of QT interval prolongation in the FAERS database from the period 2004–2022. Reporting odds ratio (ROR) was performed to quantify the signals of ADEs.
Results
We listed the top 40 drugs that caused QT interval prolongation. Among them, the 3 drugs with the highest number of cases were quetiapine (1,151 cases, ROR = 7.62), olanzapine (754 cases, ROR = 7.92), and citalopram (720 cases, ROR = 13.63). The two most frequently reported first-level Anatomical Therapeutic Chemical (ATC) groups were the drugs for the nervous system ( n = 19, 47.50%) and antiinfectives for systemic use ( n = 7, 17.50%). Patients with missing gender ( n = 3,482, 23.68%) aside, there were more females (7,536, 51.24%) than males (5,158, 35.07%) were involved. 3,720 patients (25.29%) suffered serious clinical outcomes resulting in deaths or life-threatening conditions. Overall, most drugs that caused QT interval prolongation had early failure types according to the assessment of the Weibull's shape parameter (WSP) analysis.
Conclusions
Our study offered a list of drugs that frequently caused QT interval prolongation based on the FAERS system, along with a description of some risk profiles for QT interval prolongation brought on by these drugs. When prescribing these drugs in clinical practice, we should closely monitor the occurrence of ADE for QT interval prolongation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China.
- Office of Good Clinical Practice, Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China.
- Department of Pharmacy, Mianyang Central Hospital, Mianyang, Sichuan, China.
- Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zitieren
APA
Tan, H., Yan, X., Chen, Y., Huang, G., Luo, L., Li, W., Lan, W., Chen, C., & Xi, X. (2024). A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1363382
Vancouver
Tan H, Yan X, Chen Y, Huang G, Luo L, Li W, et al. A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS. Frontiers in Cardiovascular Medicine. 2024;11. doi:10.3389/fcvm.2024.1363382
BibTeX
@article{Tan2024,
author = {Tan, Haowen and Yan, Xida and Chen, Ying and Huang, Guili and Luo, Luping and Li, Wenjun and Lan, Weiwei and Chen, Cheng and Xi, Xin},
title = {A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS},
journal = {Frontiers in Cardiovascular Medicine},
year = {2024},
volume = {11},
doi = {10.3389/fcvm.2024.1363382}
}
EUVIMED